Comments
Jubilant Life Sciences Ltd today said that it has received approval from the US Food and Drug Administration (USFDA) to market generic versions of GlaxoSmithKline’s anti-depressant Wellbutrin SR and smoking cessation aid Zyban.
The abbreviated new drug application (ANDA) approval for bupropion hydrochloride extended-release tablets, the generic version of Wellbutrin SR, is in multiple strengths of 100 mg, 150 mg and 200 mg, Jubilant Life Sciences said in a filing to the BSE.
For bupropion hydrochloride extended-release tablets, the generic version of Zyban, the approval is for 150 mg, the company added.
“We expect to launch these products in Q3 FY’14,” it said.
Quoting IMS data, the company said the current total market size of these products in the US is $518 million per annum.
As of June 30, 2013, Jubilant Life Sciences had 649 filings for formulations, including 58 ANDAs filed in the US and 41 Dossier filings in Europe. Of these, 189 have been approved in various regions of the world, the company said.
Shares of Jubilant Life Sciences ended at Rs 75 apiece, down 0.46 per cent from their previous close on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.